Endocrine-Resistance Breast Cancers

Endocrine-resistance breast cancers

Garvan Institute of Medical Research

Treating ER+ breast cancer patients with endocrine therapy resistance

Endocrine Resistance in HR+ Metastatic Breast Cancer

Endocrine Resistance: Mechanisms and Treatment Strategies

Total Health | Oncology

Overcoming Endocrine Resistance in Breast Cancer

Advanced Breast Cancer: Challenges in Pathways Development

Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine Resistance

Breast cancer may now be caught quicker by doctors with new requirements

WTHR

CAPItello-292: capivasertib, palbociclib, and fulvestrant for HR+ endocrine-resistant breast cancer

ER and FGFR1 interaction critical in endocrine resistant breast cancer

Endocrine therapy resistance in ER+ metastatic breast cancer

Epigenetic Therapy Targets the 3D Epigenome in Endocrine-Resistant Breast Cancer

Circumventing Endocrine Resistance in Breast Cancer

Dr. Goldstein on Endocrine Resistance Therapy in Early- Stage Breast Cancer

Targeted Oncology

Dr. Ellis on Resistance to Endocrine Therapy in HR+ Metastatic Breast Cancer

Dr. O'Regan on Endocrine Therapy Resistance in Breast Cancer

Buparlisib helps overcome endocrine resistance in metastatic breast cancer: BELLE-2 trial results

Treatment of endocrine resistant breast cancer Dr. Amin Eltigani

Oncology Events

Joanna Achinger-Kawecka: "3D Epigenome Remodelling in the Endocrine-Resistant Breast Cancer"

Fragile Nucleosome

Emerging mechanisms of resistance to endocrine therapies in HR+ breast cancer